News | March 30, 2022
TDB approves funding for MIM in MedTech
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Technology Development Board supports commercialisation of Metal Injection Molding of implants
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Subscribe To Our Newsletter & Stay Updated
